Health Robotics' i.v.STATION ONCO Expands Global Footprint With Dominican Republic's Macrotech Farmaceutica

BOZEN, SUD-TIROL, Italy, June 1, 2011 -

Health Robotics today announced a new exclusive distribution agreement
for its world-leading i.v.STATION ONCO, i.v.SOFT, and i.v.STATION products
with Dominican Republic-based leader Macrotech Farmaceutica. This new
exclusive partnership represents Health Robotics' entry into its 20th new
country over the past 2 years, persisting on its worldwide quest to
pervasively provide safe and cost-effective Intravenous Admixture Compounding
Automation to hospitals all over the world.

"On the heels of our recent market entrance in Latin America and the
continued success in the USA and Canada with 10 new contracts this quarter,
this new exclusive partnership with Macrotech represents the realization that
our vision for networked and redundant Oncology compounding devices is
rapidly taking hold all over the American continent", stated Gaspar DeViedma,
Health Robotics' Executive Vice President.

i.v.STATION ONCO represents Health Robotics' second generation Cancer
Therapy Compounding robot for syringes and I.V. Bags, introduced into the
market well before our competitors can even install their first solutions at
any global hospital, despite their 20+ year old fictional claims[1]. Amongst
the technology innovations pioneered by i.v.STATION ONCO are its: ability to
handle pre-attached lines to IV Bags; small footprint [at 15% to 25% of the
size/weight of other marketed robots]; faster throughput [up to 40 doses per
hour]; automated tamper-evident syringe capping; and RFID support.

"Our upcoming installation of i.v.STATION and i.v.SOFT Assist in 2011
followed by i.v.STATION ONCO in early 2012 represents a major milestone for
our company and for the exponential improvement of safe and sterile
compounding at our customer sites. We are all very excited at Macrtotech
Farmaceutica to complete Health Robotics' technical training this Summer, and
to conduct already scheduled safe-compounding strategy sessions with Gaspar
DeViedma and our regional thought leaders throughout this Fall", stated
Joaquin Toribio, Macrotech's General Manager.

About Macrotech Farmaceutica:

With locations in Santo Domingo, Miami, and other key sites throughout
the Caribbean, Macrotech Farmaceutica is a pharmaceutical and biomedical
engineering leader in the healthcare sector, focusing on the distribution and
service for Intravenous solutions, medications, and sophisticated medical
equipment, such as Baxter, Incol, Alpha, Stryker, and Globix. For additional
information, please visit: www.mf.com.do/

About Health Robotics:

Health Robotics is the undisputed global leading supplier of
life-critical intravenous medication robots, providing over 175 hospital
installations in 6 continents with robotics technology and software
automation solutions deployed utilizing virtual high-availability technology.
Its world-leading solutions CytoCare(R) and i.v.STATION(R) ONCO [hazardous
IVs], i.v.STATION(R) [non-hazardous IVs], i.v.SOFT(R) [workflow engine for
manual compounding], MEDarchiver(R) [life-critical clinical information
system], and TPNstation(TM) [totally-automated parenteral nutrition] have and
will greatly contribute to ease hospitals' growing pressures to improve
patient safety, increase throughput and contain costs. Through the effective
and efficient production of sterile, accurate, tamper-evident and
ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate
life-threatening drug and diluent exchange errors, decrease other medical
mistakes and sterility risks, work more efficiently, reduce waste and
controlled substances' diversion, and diminish the gap between rising patient
volume/acuity and scarce medical, nursing, and pharmacy staff. For more
information, please visit: www.health-robotics.com

    For additional information, please contact:
    Claudia Flaim, Marketing Coordinator
    flaim@health-robotics.com
    Phone: +39-0471-200-372

    ---------------------------------

    [1]Am J Hosp Pharm 46(11): 2286-93 1989

.